SCHEMBL3461803

SCHEMBL3461803

CC(C)CCCCCc1cc(O)ccc1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 6/20 0.49
ALOX15 P16050 3/20 0.49
CYP3A4 P08684 3/20 0.49
TP53 P04637 2/20 0.49
MEN1 O00255 2/20 0.49
TSHR P16473 2/20 0.49
KMT2A Q03164 2/20 0.49
ALOX5 P09917 1/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
EGFR P00533 3/20 0.41
MAP1LC3B Q9GZQ8 1/20 0.41
MAP1LC3A Q9H492 1/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29457621 1.00 TYR (0.49) TYRALOX15CYP3A4TP53MEN1
SCHEMBL10783247 1.00 TYR (0.49) TYRALOX15CYP3A4TP53MEN1
SCHEMBL69672 0.93 TYR (0.47) TYRALOX15CYP3A4TP53MEN1
SCHEMBL5654220 0.86 TYR (0.67) TYRALOX15CYP3A4TP53MEN1
SCHEMBL11158300 0.85 TYR (0.55) TYRALOX15CYP3A4TP53EGFR
SCHEMBL13065628 0.85 TYR (0.57) TYRALOX15CYP3A4TP53MEN1
SCHEMBL8465007 0.85 GABRA1 (0.50) ALOX15CYP3A4MEN1TSHRKMT2A
SCHEMBL2546062 0.85 AMY1A (0.46) TYRALOX15CYP3A4TP53MEN1
SCHEMBL9504221 0.85 AMY1A (0.46) TYRALOX15CYP3A4TP53MEN1
SCHEMBL9500618 0.85 AMY1A (0.46) TYRALOX15CYP3A4TP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673997-B2 Work time to walk-on time ratio by adding a phenolic catalyst to polyaspartic flooring formulations COVESTRO LLC (US) 2023-06-13 US claimed
CN-114144454-A Improved operating time to open-run time ratio by adding phenolic catalysts to polyaspartic flooring formulations 科思创有限公司 2022-03-04 CN claimed
US-20210032407-A1 WORK TIME TO WALK-ON TIME RATIO BY ADDING A PHENOLIC CATALYST TO POLYASPARTIC FLOORING FORMULATIONS COVESTRO LLC 2021-02-04 US claimed
US-20100168279-A1 THERMALLY CURABLE EPOXY-AMINE BARRIER SEALANTS HENKEL AG & CO. KGAA (DE) 2010-07-01 US claimed
EP-2001924-A1 THERMALLY CURABLE EPOXY-AMINE BARRIER SEALANTS National Starch and Chemical Investment Holding Corporation (US) 2008-12-17 EP claimed
WO-2007114822-A1 THERMALLY CURABLE EPOXY-AMINE BARRIER SEALANTS NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 2007-10-11 WO claimed
US-20250257167-A1 EXTENDED WORK TIME POLYASPARTIC FLOOR COATING FORMULATIONS COVESTRO LLC 2025-08-14 US disclosed
EP-4526362-A1 EXTENDED WORK TIME POLYASPARTIC FLOOR COATING FORMULATIONS Covestro LLC (US) 2025-03-26 EP disclosed
EP-4321551-A1 EXTENDED WORK TIME POLYASPARTIC FLOOR COATING FORMULATIONS Covestro LLC (US) 2024-02-14 EP disclosed
WO-2023224846-A1 EXTENDED WORK TIME POLYASPARTIC FLOOR COATING FORMULATIONS COVESTRO LLC (US) 2023-11-23 WO disclosed
US-11673997-B2 Work time to walk-on time ratio by adding a phenolic catalyst to polyaspartic flooring formulations COVESTRO LLC (US) 2023-06-13 US disclosed
CN-114144454-A Improved operating time to open-run time ratio by adding phenolic catalysts to polyaspartic flooring formulations 科思创有限公司 2022-03-04 CN disclosed
US-20210032407-A1 WORK TIME TO WALK-ON TIME RATIO BY ADDING A PHENOLIC CATALYST TO POLYASPARTIC FLOORING FORMULATIONS COVESTRO LLC 2021-02-04 US disclosed
US-20080081831-A1 PEPTIDOMIMETIC MODULATORS OF CELL ADHESION ADHEREX TECHNOLOGIES, INC. (CA) 2008-04-03 US disclosed
WO-2007114822-A1 THERMALLY CURABLE EPOXY-AMINE BARRIER SEALANTS NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 2007-10-11 WO disclosed
US-7268115-B2 Cyclic peptides; three-dimensional structures; screening; anticancer agents; angiogenesis inhibitors; drug delivery ADHEREX TECHNOLOGIES, INC. (CA) 2007-09-11 US disclosed
EP-0849633-B1 Photographic recording materials and their use in redox amplification EASTMAN KODAK CO (US) 2003-03-05 EP disclosed
US-6127107-A SUPPORT COATED WITH EMULSION LAYERS CONTAINING EACH A COLOR-FORMING COUPLER DEVELOPABLE BY REDOX DEVELOPMENT FOLLOWED DIRECTLY BY A BLEACH-FIX STEP WITHOUT STAINING EASTMAN KODAK COMPANY (US) 2000-10-03 US disclosed
US-6063553-A SUBJECTING IMAGEWISE EXPOSED PHOTOGRAPHIC RECORDING MATERIAL TO DEVELOPMENT/AMPLIFICATION SOLUTION COMPRISING COLOR DEVELOPING AGENT AND OXIDIZING AGENT AND, AFTER REDOX DEVELOPMENT, SUBJECTING PHOTOGRAPHIC MATERIAL TO BLEACH FIXING EASTMAN KODAK COMPANY (US) 2000-05-16 US disclosed
EP-0849633-A1 Photographic recording materials and their use in redox amplification EASTMAN KODAK COMPANY (US) 1998-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081831-A1 PEPTIDOMIMETIC MODULATORS OF CELL ADHESION CDH1, EPCAM, VCAM1 TYR 4412/4885ALOX15 3148/4885CYP3A4 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.